Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Plasma Cell Neoplasm
Conditions
Keywords
adult acute myeloid leukemia 11q23 (MLL) abnormalities, adult acute myeloid leukemia inv(16)(p13;q22), adult acute myeloid leukemia t(15;17)(q22;q12), adult acute myeloid leukemia t(16;16)(p13;q22), adult acute myeloid leukemia t(8;21)(q22;q22), accelerated phase chronic myelogenous leukemia, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, chronic phase chronic myelogenous leukemia, de novo myelodysplastic syndromes, extranodal marginal zone B-cell lymphoma, mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, stage I adult Burkitt lymphoma, contiguous stage II adult Burkitt lymphoma, noncontiguous stage II adult Burkitt lymphoma, Waldenstrom macroglobulinemia, noncontiguous stage II adult immunoblastic, contiguous stage II adult immunoblastic, large cell lymphoma, stage I adult immunoblastic large cell lymphoma, previously treated myelodysplastic syndromes, recurrent adult Burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, refractory multiple myeloma, relapsing chronic myelogenous leukemia, secondary acute myeloid leukemia, secondary myelodysplastic syndromes, splenic marginal zone lymphoma, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, stage III adult Burkitt lymphoma, stage III adult diffuse large cell lymphoma, stage III adult immunoblastic large cell lymphoma, stage III adult lymphoblastic lymphoma, stage IV adult immunoblastic large cell lymphoma, stage IV adult lymphoblastic lymphoma, refractory anemia with excess blasts in transformation, refractory anemia with excess blasts, refractory anemia, prolymphocytic leukemia, contiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, refractory chronic lymphocytic leukemia, stage IV adult Burkitt lymphoma, stage I childhood small noncleaved cell lymphoma, stage II childhood small noncleaved cell lymphoma, stage III childhood small noncleaved cell lymphoma, stage IV childhood small noncleaved cell lymphoma, recurrent childhood small noncleaved cell lymphoma, stage I childhood large cell lymphoma, stage II childhood large cell lymphoma, stage III childhood large cell lymphoma, stage IV childhood large cell lymphoma, contiguous stage II mantle cell lymphoma, contiguous stage II adult lymphoblastic lymphoma, noncontiguous stage II adult lymphoblastic lymphoma, noncontiguous stage II mantle cell lymphoma, stage III mantle cell lymphoma, stage IV mantle cell lymphoma, stage I mantle cell lymphoma, stage I adult lymphoblastic lymphoma, stage I adult diffuse large cell lymphoma, stage IV adult diffuse large cell lymphoma, recurrent childhood large cell lymphoma, stage I childhood lymphoblastic lymphoma, stage II childhood lymphoblastic lymphoma, stage III childhood lymphoblastic lymphoma, stage IV childhood lymphoblastic lymphoma, recurrent childhood lymphoblastic lymphoma, childhood myelodysplastic syndromes, Burkitt lymphoma
Brief summary
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic cancer. In this study, the safety and tolerability of CLT-008 administered 24 hours after an umbilical cord blood transplant will be determined by monitoring for adverse reactions, neutrophil and platelet recovery, hematopoietic chimerism, graft-versus-host disease (GVHD), and infections.
Interventions
BIOLOGICALhuman myeloid progenitor cells
Single intravenous injection/infusion
Sponsors
Department of Health and Human Services
Cellerant Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Undergoing allogeneic (4-6/6 matched) umbilical cord blood graft with at least 2.5 x 10e7 cells/kg for hematological malignancy: * High risk acute myeloid leukemia (AML) in complete remission * Very high risk pediatric AML; patients \<21 years eligible with \<25% blasts in marrow after failed chemotherapy * High risk acute lymphocytic leukemia (ALL) in complete remission * Chronic myelogenous leukemia (CML), excluding refractory blast crisis * Myelodysplasia (MDS) IPPS Int-2 or high risk, or refractory anemia with severe pancytopenia or high risk cytogenetics * Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), marginal zone B-cell lymphoma or follicular lymphoma that have progressed after two prior therapies * Lymphoplasmacytic, lymphoma, mantle-cell lymphoma, prolymphocytic leukemia after initial therapy and complete or partial remission * Large cell non-Hodgkin lymphoma (NHL) in second complete or partial remission (chemotherapy refractory large cell NHL not eligible) * Lymphoblastic lymphoma, peripheral T cell lymphoma including angioimmunoblastic lymphoma, Burkitt's lymphoma, and other high-grade NHL after initial therapy if stage III/IV in complete or partial remission, or after progression if stage I/II \<1 year (chemotherapy refractory high-grade NHL not eligible) * Multiple myeloma beyond 2nd partial remission * Preparative regimen consisting of cyclophosphamide, fludarabine, and total body irradiation * Adequate organ function Key
Exclusion criteria
* Symptomatic underlying pulmonary disease or requiring oxygen * Active infection * HIV positive * Pregnant or nursing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability | 100 days post transplant |
Secondary
| Measure | Time frame |
|---|---|
| Neutrophil and platelet recovery | 100 days post transplant |
| Persistence of CLT-008 derived cells | 100 days post transplant |
| Graft-versus-host disease (GVHD) | 100 days post transplant |
| Non-relapse mortality | 100 days post transplant |
| Infections | 42 days post transplant |
Countries
United States
Outcome results
None listed